Burden of Disease in Myasthenia Gravis

Myasthenia Gravis Clinical Trial

— Mya-BoD  

Official title:

Questionnaire Survey on the Systematic Recording and Characterization of Quality of Life Limitations in Myasthenia Gravis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03979521
• Other study ID #: Mya-BoD
• Status: Completed
• Start date: May 1, 2019
• Est. completion date: July 31, 2019

Study information

• Verified date: December 2021
• Source: Charite University, Berlin, Germany
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Questionnaire-based survey addressed to german patients with the chronic autoimmune muscle disease called myasthenia gravis regarding quality of life, socioeconomic impact, social support, course of disease, complications of therapy and psychological comorbidities.

Description:

Background:

Myasthenia gravis is a rare, chronic, antibody-mediated autoimmune disease that results in muscular weakness. The patients suffer from symptoms such as visual disturbances (especially double vision), weakness in the arms and legs, chewing and swallowing disorders and respiratory disorders, as well as crisis-related worsening of ventilation. This is often accompanied by pronounced fatigue (physical) and mental fatigue (depression).

Despite drug therapies that are on one hand symptomatic improving muscle strength, and on the other hand modulating the immune system, as well as specific procedures and drugs used in crises (plasmapheresis, immunoglobins) or refractory patients, patients are often severely limited, affecting everyday activities of self-care, family, social and professional life, thus affecting the mood and quality of life of patients. There is a lack of data measuring quality of life adequately.

Aim:

The aim of the data collection is to record the quality of life of myasthenia patients. By clinical information on the disease (including symptoms, course and therapy) and recording the social and occupational situation, the data should be contextualized. The following hypotheses are to be confirmed:

Primary hypotheses

• Myasthenia gravis affects the quality of life of patients comparable to neurological diseases such as multiple sclerosis

• Patients are limited in their participation in their private and professional life

• The severity of the disease is associated with the quality of life. Secondary hypotheses

• Myasthenia is associated with income busses and other economic disadvantages of the night

• Quality of life in myasthenia patients is related to fatigue and depression

• Quality of life in myasthenia patients depends on different therapy methods

• Myasthenia gravis has an impact on family planning and care for children.

Methods:

In cooperation with the German Myasthenia Gravis Society, a questionnaire prepared by the Charité will be sent to its members with a request for completion and an anonymous return. Similar projects have already been implemented in the past (response rate> 30%). About 3,300 patients should be contacted.

The returned questionnaires are then statistically evaluated and presented as part of a publication. For the evaluation of the hypotheses suitable descriptive, univariate analysis methods are used. Furthermore, with sufficient case numbers, multivariate analyzes (e.g., logistic regression) are also planned.

The questionnaire contains general information and questions about:

• Education and employment

• Social situation

• Social Support

• Economic aspects

• Symptoms and severity, course, treatment of myasthenia

• Quality of life

• Fatigue and depression

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1680
• Est. completion date: July 31, 2019
• Est. primary completion date: July 31, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with Myasthenia Gravis

• Age =18 years

Exclusion Criteria:

• none

Related Conditions & MeSH terms

• Muscle Weakness
• Myasthenia Gravis

Locations

Country	Name	City	State
Germany	NeuroCure Clinical Research Center (NCRC), Charité University, Berlin	Berlin-Mitte

Sponsors (2)

Lead Sponsor	Collaborator
Charite University, Berlin, Germany	NeuroCure Clinical Research Center, Charite, Berlin

Country where clinical trial is conducted

Germany, 

References & Publications (1)

Lehnerer S, Jacobi J, Schilling R, Grittner U, Marbin D, Gerischer L, Stascheit F, Krause M, Hoffmann S, Meisel A. Burden of disease in myasthenia gravis: taking the patient's perspective. J Neurol. 2021 Nov 20. doi: 10.1007/s00415-021-10891-1. [Epub ahea — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Questionnaire for self-completion by patients containing questions about general information, information on myasthenia, information socioeconomic situation		directly after inclusion in the study
Primary	Hospital Anxiety and Depression Scale (HADS)	Questionnaire for self-completion by patients to determine the levels of anxiety and depression	directly after inclusion in the study
Primary	Mya Quality of Life 15 (Mya QoL15)	Questionnaire for self-completion by patients for use as a measure of health outcome	directly after inclusion in the study
Primary	Medical Outcomes Study Questionnaire Short Form 36 Health Survey (SF36)	Questionnaire for self-completion by patients for patients health	directly after inclusion in the study
Primary	Myasthenia gravis Activities of daily living (MG ADL)	Questionnaire for self-completion by patients to determine symptom severity and limitations in activities of daily living	directly after inclusion in the study